4D Molecular Therapeutics, Inc. (FDMT) stock
FDMTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/302% above fair value
$12.23+0.12 (+0.95%)
Close on Nov 13, 2026Market cap $882.76MP/E –Yield –
4D Molecular Therapeutics price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
4D Molecular Therapeutics's price to book ratio was 1.8× on Nov 11, 2026, against 1.5× a year earlier. Over the last 5 years it ranged from 0.3× to 4.5×, with a median of 1.4×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 1.8× | +0.8 |
| 2025 | Dec 31, 2025 | 1.0× | +0.4 |
| 2024 | Dec 31, 2024 | 0.5× | −2.1 |
| 2023 | Dec 29, 2023 | 2.6× | −0.2 |
| 2022 | Dec 30, 2022 | 2.9× | +0.2 |
| 2021 | Dec 31, 2021 | 2.7× | – |
See a number that looks wrong?